Ardelyx (ARDX) Cash & Current Investments (2013 - 2026)
Ardelyx (ARDX) reported Cash & Current Investments of $238.1 million for Q1 2026, up 11.27% on a YoY basis from $214.0 million in Q1 2025, and down 10.06% quarter-over-quarter from $264.7 million in Q4 2025.
Ardelyx (ARDX) Cash & Current Investments (2013 - 2026) Analysis & Trends
Ardelyx has reported Cash & Current Investments for 14 years, with the latest figure at $238.1 million in Q1 2026.
- For the quarter ending Q1 2026, Cash & Current Investments rose 11.27% year-over-year to $238.1 million; the trailing twelve-month figure through Mar 2026 stood at $238.1 million (up 11.27% YoY), and the FY2025 full-year result was $264.7 million, up 5.83% from the prior year.
- Cash & Current Investments for Q1 2026 stood at $238.1 million, down from $264.7 million in the prior quarter.
- The five-year high for Cash & Current Investments was $264.7 million in Q4 2025, with the low at $81.0 million in Q2 2022.
- Historically, Cash & Current Investments has averaged $177.6 million across 5 years, with a median of $186.0 million in 2024.
- Annual changes were most pronounced in 2022 — Cash & Current Investments plunged 52.85% — and 2023, when it soared 82.16%.
- Ardelyx's Cash & Current Investments stood at $123.9 million in 2022, then surged by 48.74% to $184.3 million in 2023, then jumped by 35.7% to $250.1 million in 2024, then climbed by 5.83% to $264.7 million in 2025, then decreased by 10.06% to $238.1 million in 2026.
- The last three Cash & Current Investments figures came in at $238.1 million (Q1 2026), $264.7 million (Q4 2025), and $242.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 2.13 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 7.20 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 7.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ardelyx | 1.49 Bn | 1.25 Bn | 89.66 Mn | 238.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 238.07 Mn |
| Dec 31, 2025 | 264.69 Mn |
| Sep 30, 2025 | 242.71 Mn |
| Jun 30, 2025 | 238.45 Mn |
| Mar 31, 2025 | 213.95 Mn |
| Dec 31, 2024 | 250.10 Mn |
| Sep 30, 2024 | 190.40 Mn |
| Jun 30, 2024 | 185.96 Mn |
| Mar 31, 2024 | 202.58 Mn |
| Dec 31, 2023 | 184.30 Mn |
| Sep 30, 2023 | 165.08 Mn |
| Jun 30, 2023 | 127.58 Mn |
| Mar 31, 2023 | 130.37 Mn |
| Dec 31, 2022 | 123.91 Mn |
| Sep 30, 2022 | 90.62 Mn |
| Jun 30, 2022 | 81.01 Mn |
| Mar 31, 2022 | 89.70 Mn |
| Dec 31, 2021 | 116.69 Mn |
| Sep 30, 2021 | 141.65 Mn |
| Jun 30, 2021 | 171.81 Mn |